By Katherine Hamilton
Genmab has stopped clinical development of a blood cancer treatment after Johnson & Johnson decided it won't exercise its option to license it.
The Copenhagen, Denmark, biotechnology company said Monday Johnson & Johnson has decided it won't exercise its option to receive a worldwide license to develop, manufacture and commercialize HexaBody-CD38, which is designed to treat people with certain blood cancers.
Genmab will not pursue further clinical development of the drug, it said, after evaluating the data, market landscape and its own portfolio prioritization.
Genmab had provided Johnson and Johsnon with data from a clinical proof-of-concept study for HexaBody-CD38 to treat multiple myeloma. Preliminary data demonstrated an overall response rate of 55%, while the rate of very good partial response or better was 29% and complete response or better was 7%.
Johnson & Johnson's decision does not impact Genmab's 2025 financial guidance, it said.
Write to Katherine Hamilton at katherine.hamilton@wsj.com
(END) Dow Jones Newswires
March 10, 2025 10:43 ET (14:43 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。